Loading...
•
Sep 30, 2022
Tscan Therapeutics Q3 2022 Earnings Report
TScan Therapeutics reported financial results and provided a business update.
Key Takeaways
TScan Therapeutics reported Q3 2022 financial results, highlighting progress in their pipeline, including the opening of four sites for their hematologic malignancies program and the completion of a pre-IND meeting with the FDA for their solid tumor program. The company ended the quarter with $137.3 million in cash and cash equivalents, which is expected to fund operations into Q2 2024.
Four sites for the hematologic malignancies program are open and enrolling patients.
Completed pre-IND meeting with the FDA for the solid tumor program.
Ended the quarter with cash and cash equivalents of $137.3 million, funding operations into Q2 2024.
A virtual investor event is scheduled for November 14 to highlight clinical trial design.
Tscan Therapeutics
Tscan Therapeutics
Forward Guidance
TScan plans to progress IND-enabling studies for its solid tumor programs and submit IND applications for two MAGE-A1 TCRs (TSC-204-A2 and TSC-204-C7) by the end of 2022. The Company plans to file INDs for HPV (TSC-200-A2) and PRAME (TSC-203-A2) in the first half of 2023 with two additional INDs to be filed by the end of 2023. The Company expects to release preliminary clinical safety data for the most advanced TCRs by the end of 2023.
Positive Outlook
- Progress IND-enabling studies for solid tumor programs
- Submit IND applications for two MAGE-A1 TCRs (TSC-204-A2 and TSC-204-C7) by the end of 2022
- File INDs for HPV (TSC-200-A2) and PRAME (TSC-203-A2) in the first half of 2023
- File two additional INDs by the end of 2023
- Release preliminary clinical safety data for the most advanced TCRs by the end of 2023